Opendata, web and dolomites

PREMEDiCARE SIGNED

PREcision MEDicine with induced pluripotent stem cells for Cardiac Arrhythmias Risk Evaluation

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 PREMEDiCARE project word cloud

Explore the words cloud of the PREMEDiCARE project. It provides you a very rough idea of what is the project "PREMEDiCARE" about.

cardiac    clinical    models    hpsc    long    safe    diagnosis    precision    humans    death    pathogenic    assays    qt    arrhythmia    links    proarrhythmic    population    molecular    reduce    therapeutic    electrophysiological    risk    male    hipsc    vitro    severe    prolongation    profound    unpredictable    caused    pharmacological    acquired    identical    phenotypes    poorly    carriers    severity    applicable    characterised    patient    families    cms    congenital    contractile    physiological    create    simulate    mutations    female    manifestations    combines    vulnerable    treatments    stratification    lqts    syndromes    medicine    pipeline    arrhythmogenic    therapy    patients    advancements    rare    human    asymptomatic    preclinical    mutation    protect    vs    subjects    uses    matched    screenings    electrocardiogram    animal    shift    interdisciplinary    pluripotent    safer    phenotype    sudden    susceptibility    genetic    interval    drug    stem    cardiomyocytes    disease    revealed    genotype    shape    drugs    cells    first    arrhythmias    syndrome    reproduce    personalised    symptomatic    predisposed   

Project "PREMEDiCARE" data sheet

The following table provides information about the project.

Coordinator
ISTITUTO AUXOLOGICO ITALIANO 

Organization address
address: VIA L. ARIOSTO 13
city: MILANO
postcode: 20145
website: www.auxologico.it

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Total cost 168˙277 €
 EC max contribution 168˙277 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2017
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2018
 Duration (year-month-day) from 2018-10-01   to  2020-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ISTITUTO AUXOLOGICO ITALIANO IT (MILANO) coordinator 168˙277.00

Map

 Project objective

Long QT Syndrome (LQTS) is a severe arrhythmogenic condition characterised by the prolongation of the QT interval on the electrocardiogram. It is caused by genetic factors (congenital) or drugs (acquired) and sudden cardiac death can be the first manifestations of the disease. Advancements in genetic screenings have revealed profound links between genotype and phenotype for LQTS, improving diagnosis, risk stratification and therapy; However, it is still poorly understood why patients with identical pathogenic mutations have different clinical phenotypes, which factors are involved in this unpredictable disease severity and how we can protect these subjects from drug treatments that are safe in the general population. We do need improved and more physiological in vitro models to simulate arrhythmias in vitro, effective for drug testing, to identify, evaluate and study factors that shape the arrhythmogenic risk in vulnerable subjects. Here I propose a precision medicine approach that uses human pluripotent stem cells-derived cardiomyocytes (hPSC-CMs) from LQTS families (rare resources that include male, female, symptomatic and asymptomatic patients) to: i) demonstrate that the hiPSC technology can reproduce in vitro the clinical disease severity observed in symptomatic vs asymptomatic LQTS mutation carriers; ii) create an in vitro interdisciplinary pharmacological approach with proarrhythmic drugs which combines matched electrophysiological, contractile, molecular and genetic assays; iii) identify and evaluate the factors affecting the arrhythmogenic risk in predisposed subjects. This pipeline to assess arrhythmia susceptibility from patient-specific hiPSC-CMs can be applicable to other arrhythmogenic syndromes. The results of this project will contribute to reduce the use of animal models in preclinical research, to create safer, more effective drugs for humans and to promote the shift of new therapeutic approaches towards precision or personalised medicine.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PREMEDICARE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PREMEDICARE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

Widow Spider Mating (2020)

Immature mating as a novel tactic of an invasive widow spider

Read More  

TARGET SLEEP (2020)

Boosting motor learning through sleep and targeted memory reactivation in ageing and Parkinson’s disease

Read More  

LieLowerBounds (2019)

Lower bounds for partial differential operators on compact Lie groups

Read More